Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Haematology

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ejh.13065PMID 29569742
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic lymphocytic leukaemia.

  2018cited by this paper
• Chronic lymphocytic leukaemia

  2017cited by this paper
• Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

  2016cited by this paper
• Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

  2016cited by this paper
• T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

  2016cited by this paper
• Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma

  2015cited by this paper
• Chronic lymphocytic leukaemia

  2015cited by this paper
• Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia

  2015cited by this paper
• Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

  2015cited by this paper
• Initial treatment of CLL: integrating biology and functional status.

  2015cited by this paper
• Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

  2014cited by this paper
• Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

  2014cited by this paper
• Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.

  2014cited by this paper
• Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).

  2013cited by this paper
• Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

  2013cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Lenalidomide enhances anti-myeloma cellular immunity

  2012cited by this paper
• Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses

  2012cited by this paper
• Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

  2012cited by this paper
• T cell assays and MIATA: the essential minimum for maximum impact.

  2012cited by this paper
• Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

  2012cited by this paper
• Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

  2010cited by this paper
• Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

  2010cited by this paper
• Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.

  2009cited by this paper
• Generation of a Dendritic Cell‐based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large‐scale Production

  2009cited by this paper
• The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

  2009cited by this paper
• Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.

  2009cited by this paper
• CCR1 Is Required for Treg-Mediated Protection From Lethal Acute Graft-Versus-Host Disease.

  2009cited by this paper
• Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.

  2009cited by this paper
• Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response

  2008cited by this paper
• Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

  2008cited by this paper
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia

  2005cited by this paper
• Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL

  2004cited by this paper
• CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

  2004cited by this paper
• Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.

  2003cited by this paper
• Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell–tumour hybrids in B-CLL

  2003cited by this paper
• Combinations of anticancer drugs and immunotherapy

  2003cited by this paper
• The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

  2002cited by this paper
• Designer cancer vaccines are still in fashion

  2000cited by this paper
• Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.

  2000cited by this paper
• Autologous T lymphocytes recognize the tumour‐derived immunoglobulin VH‐CDR3 region in patients with B‐cell chronic lymphocytic leukaemia

  2000cited by this paper
• New insights into the mobilization and phagocytic activity of dendritic cells

  1996cited by this paper

• Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges

  2026cites this paper
• Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

  2022cites this paper
• Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling.

  2022cites this paper
• Cell‐Based Bio‐Hybrid Delivery System for Disease Treatments

  2021cites this paper
• Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy

  2020cites this paper
• The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia

  2020cites this paper
• Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma

  2020cites this paper
• Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia

  2020cites this paper
• A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)

  2020cites this paper
• Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine

  2019cites this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cites this paper
• Can Dendritic Cell Vaccination Prevent Leukemia Relapse?

  2019cites this paper
• Trial Watch: Toll-like receptor agonists in cancer immunotherapy

  2018cites this paper
• Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications

  2018cites this paper